Year All2026202520242023202220212020 Mar 02, 2026 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 24, 2026 Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston Feb 19, 2026 Candel Therapeutics Announces Proposed $100 Million Public Offering Feb 19, 2026 Candel Therapeutics Announces Pricing of Public Offering Feb 19, 2026 Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Feb 11, 2026 Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit Feb 02, 2026 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 24, 2026 Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
Feb 19, 2026 Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
